chloroprocaine
Small molecule
Evidence outlook
Approved: Ocular Surface Anesthesia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Figus et al. (J Ocul Pharmacol Ther, 2024; PMID 38489057) report different figures for this outcome: anaesthesia success in 152 of 166 patients with chloroprocaine and 153 of 172 with tetracaine.
track record: Partial signal
Also approved (1)
- IHEEZO (chloroprocaine hydrochloride ophthalmic gel 3%) for ocular surface anesthesia during ophthalmologic procedures in adults
Company guidance: topline data expected fourth quarter of 2026 (Harrow, Inc., 10 Aug 2026). “IHEEZO (QUELL): Topline data from QUELL, a prospective, randomized, multi-center clinical trial evaluating IHEEZO in patients undergoing intravitreal injections, are expected in the fourth quarter of 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04685538 NCT04685538 · Cataract This randomized, observer-masked, multicentre Phase 3 equivalence trial compared chloroprocaine 3% gel with tetracaine 0.5% eye drops in 338 patients having cataract surgery. The primary endpoint was successful surface anaesthesia without supplementation just before lens implantation. Success was 92.0% with chloroprocaine and 90.5% with tetracaine, a difference of 1.5% (95% CI -3.6 to 6.6), and the 90% CI fell within the margin of -10 to 10, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Figus 2024). Figus et al. (J Ocul Pharmacol Ther, 2024; PMID 38489057) report different figures for this outcome: anaesthesia success in 152 of 166 patients with chloroprocaine and 153 of 172 with tetracaine. Registry: NCT04685538 | 3 | Number of Participants in Each Treatment Group With a Successful Surface Anesthesia (Before Intra Ocular Lens (IOL) implantation surgery.) 2021-03-01 | Successful ocular surface anaesthesia without supplementation before lens implantation, chloroprocaine 3% gel vs tetracaine 0.5% drops: 152/166 (92.0%) vs 153/172 (90.5%); difference 1.5% (95% CI -3.6 to 6.6), 90% CI inside the -10 to 10 equivalence margin (Figus 2024, J Ocul Pharmacol Ther). | Partial signal | link ↗ |
View 2 more trials
NCT04779606 NCT04779606 · Ocular Surface Anesthesia Study 1 randomized 85 healthy volunteers 4:1 to one instillation of chloroprocaine 3% gel or placebo under double masking. The single registered primary endpoint was full conjunctival anesthesia, tested by conjunctival pinching 5 minutes after the dose. It occurred in 90% of the chloroprocaine group and 12% of the placebo group (p<0.01), so the primary endpoint was met. The study was small and enrolled healthy volunteers only. Source: the IHEEZO US label, section 14.1. Registry: NCT04779606 | 1/2 | Number of Participants Gaining Full Conjunctival Anesthesia of the Ocular Surface (Day 1) 2020-10-13 | Full conjunctival anesthesia 5 minutes after instillation (single registered primary), chloroprocaine 3% gel (IHEEZO, n=68) vs placebo (n=17): 90% vs 12%, p<0.01 (IHEEZO US label, section 14.1, Study 1). | not yet graded | link ↗ |
NCT04753710 NCT04753710 · Ocular Surface Anesthesia Study 2 randomized 60 healthy volunteers 40:20 to chloroprocaine 3% gel or placebo under double masking. The single registered primary endpoint was full conjunctival anesthesia 5 minutes after the dose. It occurred in 95% of the chloroprocaine group and 20% of the placebo group (p<0.01), so the primary endpoint was met. The study was small and in healthy volunteers. Source: the IHEEZO US label, section 14.1. Registry: NCT04753710 | 2/3 | Number of Participants in Phase 2 With Anesthesia Success (Day 1) 2020-11-06 | Anesthesia success 5 minutes after instillation (single registered primary), chloroprocaine 3% gel (IHEEZO, n=40) vs placebo (n=20): 95% vs 20%, p<0.01 (IHEEZO US label, section 14.1, Study 2). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow chloroprocaine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (2)
2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent